

**DR. DONNA SMITH OF FIRSTLAB PROVIDES TESTIMONY TO THE HOUSE SUBCOMMITTEE ON  
HIGHWAYS AND TRANSIT REGARDING DRUG AND ALCOHOL TESTING OF COMMERCIAL  
MOTOR VEHICLE DRIVERS**

Thursday, November 1, 2007, 10:00AM  
2167 Rayburn HOB

**PURPOSE OF THE HEARING**

The Committee on Transportation and Infrastructure met on Thursday, November 1, 2007 at 10:00 a.m., in 2167 Rayburn House Office Building, to receive testimony regarding vulnerabilities in the Drug and Alcohol Testing (DAT) programs administered by motor carriers. The Oversight and Investigations staff has conducted an in-depth review of conditions at facilities that perform urine collections for drug tests regulated by the Department of Transportation (DOT). The hearing will examine weaknesses in the collection process that could allow drug-using commercial drivers to disguise their drug use. We will identify the extent to which those products manufactured and sold specifically to beat drug tests affect the integrity of the drug testing process. Finally, the hearing will explore factors that enable drug-using drivers to continue to operate commercial motor vehicles and potential solutions to the identified weaknesses.

Testimony by Dr. Donna R. Smith Ed.D., Regulatory Affairs and Program Development Officer, FirstLab, Inc., on behalf of the Substance Abuse Program Administrators' Association (SAPAA) <http://transportation.house.gov/Media/File/Highways/20071101/Dr.%20Donna%20Smith.pdf>

To read the written testimony of this day's witnesses, please visit <http://transportation.house.gov/hearings/hearingdetail.aspx?NewsID=361>

The U.S. Government Accountability Office was tasked with investigating the issue to provide comprehensive information. The results of their undercover investigation can be seen here: <http://www.msnbc.msn.com/id/21568973/from/ET/>

Please check the FirstLab web site for updates on future committee reports and activities.